Comparative safety and efficacy of 2 formulations of fluticasone aqueous nasal spray in persistent allergic rhinitis

Annals of Allergy, Asthma and Immunology

Volumn 102, Issue 1, 2009, Pages 76-83

  Vaidyanathan, Sriram ^a   Barnes, Martyn ^a   Lipworth, Brian J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; CREATININE; FLUTICASONE PROPIONATE; HYDROCORTISONE; NOSE SPRAY; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CREATININE URINE LEVEL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; EYE DISEASE; FEMALE; FLOW RATE; HUMAN; HYDROCORTISONE URINE LEVEL; MALE; MINI RHINOCONJUNCTIVITIS QUALITY OF LIFE QUESTIONNAIRE; NASAL PRURITUS; NOSE CONGESTION; NOSE DISEASE; OUTCOME ASSESSMENT; PEAK NASAL INSPIRATORY FLOW; PERENNIAL RHINITIS; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SCORING SYSTEM; SNEEZING; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 59449105206     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60112-3     Document Type: Article

References (38)

1. Bousquet J, van Cauwenberge P, Khaltaev N; ARIA Workshop Group, World Health Organization. Allergic Rhinitis and its Impact on Asthma. J Allergy Clin Immunol. 2001;108:S147-S334.
2. Schatz M. A survey of the burden of allergic rhinitis in the USA. Allergy. 2007;62(suppl 85):9-16.
3. Settipane RA, Charnock DR. Epidemiology of rhinitis: allergic and nonallergic. Clin Allergy Immunol. 2007;19:23-34.
4. Schoenwetter WF, Dupclay L Jr, Appajosyula S, Botteman MF, Pashos CL. Economic impact and quality-of-life burden of allergic rhinitis. Curr Med Res Opin. 2004;20:305-317.
5. Leynaert B, Neukirch C, Liard R, Bousquet J, Neukirch F. Quality of life in allergic rhinitis and asthma: a population-based study of young adults. Am J Respir Crit Care Med. 2000;162:1391-1396.
6. Canonica GW, Bousquet J, Mullol J, Scadding GK, Virchow JC. A survey of the burden of allergic rhinitis in Europe. Allergy. 2007; 62(suppl 85):17-25.
7. van Cauwenberge P, Bachert C, Passalacqua G, et al; European Academy of Allergology and Clinical Immunology. Consensus statement on the treatment of allergic rhinitis. Allergy. 2000;55:116-134.
8. Fuller R, Johnson M, Bye A. Fluticasone propionate: an update on preclinical and clinical experience. Respir Med. 1995;89(suppl A):3-18.
9. Wiseman LR, Benfield P. Intranasal fluticasone propionate: a reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis. Drugs. 1997;53:885-907.
10. Bousquet J, van Cauwenberge P, Ait Khaled N, et al. Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GA2LEN). Allergy. 2006;61:1086-1096.
11. Meltzer EO, Rickard KA, Westlund RE, Cook CK. Onset of therapeutic effect of fluticasone propionate aqueous nasal spray. Ann Allergy Asthma Immunol. 2001;86:286-291.
12. Nielsen LP, Dahl R. Therapeutic ratio of inhaled corticosteroids in adult asthma: a dose-range comparison between fluticasone propionate and budesonide, measuring their effect on bronchial hyperresponsiveness and adrenal cortex function. Am J Respir Crit Care Med. 2000;162:2053-2057.
13. Rothman KJ. Placebo mania. BMJ. 1996;313:3-4.
14. Gomberg-Maitland M, Frison L, Halperin JL. Active-control clinical trials to establish equivalence or noninferiority: methodological and statistical concepts linked to quality. Am Heart J. 2003;146:398-403.
15. Casale TB, Azzam SM, Miller RE, Oren J; SAR Study Group. Demonstration of therapeutic equivalence of generic and innovator beclomethasone in seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 1999;82:435-441.
16. Laster LL, Johnson MF. Non-inferiority trials: the "at least as good as" criterion. Stat Med. 2003;22:187-200.
17. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(suppl 86):8-160.
18. Lund VJ, Mackay IS. Staging in rhinosinusitis. Rhinology. 1993;31: 183-184.
19. Barnes ML, Menzies D, Nair AR, Hopkinson PJ, Lipworth BJ. A proof-of-concept study to assess the putative dose response to topical corticosteroid in persistent allergic rhinitis using adenosine monophosphate challenge. Clin Exp Allergy. 2007;37:696-703.
20. Juniper EF, Thompson AK, Ferrie PJ, Roberts JN. Development and validation of the mini Rhinoconjunctivitis Quality of Life Questionnaire. Clin Exp Allergy. 2000;30:132-140.
21. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy. 1991;21:77-83.
22. Barnes ML, Ward JH, Fardon TC, Lipworth BJ. Effects of levocetirizine as add-on therapy to fluticasone in seasonal allergic rhinitis. Clin Exp Allergy. 2006;36:676-684.
23. Le Henanff A, Giraudeau B, Baron G, Ravaud P. Quality of reporting of noninferiority and equivalence randomized trials. JAMA. 2006;295: 1147-1151.
24. Epstein AM. The outcomes movement: will it get us where we want to go? N Engl J Med. 1990;323:266-270.
25. Van Hoecke H, Van Cauwenberge P. Critical look at the clinical practice guidelines for allergic rhinitis. Respir Med. 2007;101:706-714.
26. Valero A, Alonso J, Antepara I, et al. Health-related quality of life in allergic rhinitis: comparing the short form ESPRINT-15 and MiniRQLQ questionnaires. Allergy. 2007;62:1372-1378.
27. Fitzpatrick R, Davey C, Buxton MJ, Jones DR. Evaluating patient-based outcomes measures for use in clinical trials. Health Technol Assess. 1998;2:i-iv, 1-74.
28. Sims EJ, Wilson AM, White PS, Gardiner Q, Lipworth BJ. Short term repeatability and correlates of laboratory measures of nasal function in patients with seasonal allergic rhinitis. Rhinology. 2002;40:66-68.
29. Wilson AM, Sims EJ, Robb F, Cockburn W, Lipworth BJ. Peak inspiratory flow rate is more sensitive than acoustic rhinometry or rhinomanometry in detecting corticosteroid response with nasal histamine challenge. Rhinology. 2003;41:16-20.
30. Gosepath J, Amedee RG, Mann JW. Nasal provocative testing as an international standard for evaluation of allergic and nonallergic rhinitis. Laryngoscope. 2005;115:512-516.
31. Patel P, D'Andrea C, Sacks HJ. Onset of action of azelastine nasal spray compared with mometasone nasal spray and placebo in subjects with seasonal allergic rhinitis evaluated in an environmental exposure chamber. Am J Rhinol. 2007;21:499-503.
32. Berkowitz RB, Bernstein DI, LaForce C, et al. Onset of action of mometasone furoate nasal spray (NASONEX) in seasonal allergic rhinitis. Allergy. 1999;54:64 - 69.
33. Blackwelder WC. "Proving the null hypothesis" in clinical trials. Control Clin Trials. 1982;3:345-353.
34. Lipworth BJ, Jackson CM. Safety of inhaled and intranasal corticosteroids: lessons for the new millennium. Drug Saf. 2000;23: 11-33.
35. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med. 1999;159: 941-955.
36. Lipworth BJ, Seckl JR. Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids. Thorax. 1997;52:476-482.
37. McIntyre HD, Mitchell CA, Bowler SD, Armstrong JG, Wooler JA, Cowley DM. Measuring the systemic effects of inhaled beclomethasone: timed morning urine collections compared with 24 hour specimens. Thorax. 1995;50:1280-1284.
38. Bielory L, Blaiss M, Fineman SM, et al. Concerns about intranasal corticosteroids for over-the-counter use: position statement of the Joint Task Force for the American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol. 2006;96:514-525.